advanzpharma.com · 669
ADVANZ PHARMA is a trusted partner for specialty, hospital, and rare disease medicines. The company has recently announced the approval in the European Union for the new antibiotic combination EXBLIFEP(c) (cefepime/enmetazobactam) for the treatment of severe infections. Additionally, they have received positive CHMP opinion for EXBLIFEP(c). ADVANZ PHARMA has also acquired global rights to Androcur(c) from Bayer, further strengthening its global portfolio of specialty brands. In a recent development, ADVANZ PHARMA and Dimerix have entered into an Exclusive License Agreement to commercialize DMX-200 in Europe, Canada, Australia, and New Zealand. The company has also signed an exclusive agreement with GP Pharm for a peptide specialty injectable generic for multiple European countries. Stay informed about their latest press releases and news by subscribing to their updates.
